PIK3CD and neoplasm: PIK3CA mutation status did not predict the benefit of addition of pictilisib to fulvestrant either, but this was based on archived tumor specimens, which may not reflect the latest mutation status and underscores the fact that PI3K genotype may not be the most reliable biomarker of response.